Calculating the contribution of herpes simplex virus type 2 epidemics to increasing HIV incidence: Treatment implications

Clinical Infectious Diseases

Volumn 39, Issue SUPPL. 5, 2004, Pages

  Blower, Sally M ^a   Ma, Li ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b University of California   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CALCULATION; EPIDEMIC; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION RISK; INFECTION SENSITIVITY; MATHEMATICAL MODEL; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SEXUALLY TRANSMITTED DISEASE; VIRUS TRANSMISSION;

DISEASE SUSCEPTIBILITY; FEMALE; HERPES GENITALIS; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; MODELS, THEORETICAL; MONTE CARLO METHOD; PREVALENCE; RISK FACTORS; UNCERTAINTY; VIRUS SHEDDING;

EID: 7444238713     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/422361     Document Type: Article

References (49)

1. Dickerson MC, Johnston J, Delea TE, White A, Andrews E. The causal role for genital ulcer disease as a risk factor for transmission of human immunodeficiency virus: an application of the Bradford Hill criteria. Sex Transm Dis 1996; 23:429-40.
2. Fleming DT, McQuillan GM, Johnson RE, et al. Herpes simplex virus type 2 in the United States, 1976 to 1994. N Engl J Med 1997; 337:1105-11.
3. Chen CY, Ballard RC, Beck-Sague CM, et al. Human immunodeficiency virus infection and genital ulcer disease in South Africa: the herpetic connection. Sex Transm Dis 2000; 27:21-9.
4. O'Farrell N. Targeted interventions required against genital ulcers in African countries worst affected by HIV infection. Bull World Health Organ 2001; 79:569-77.
5. Quinnan GV, Masur H, Rook AH, et al. Herpesvirus infections in the acquired immune deficiency syndrome. JAMA 1984;252:72-7.
6. Stamm WE, Handsfield HH, Rompalo AM, Ashley RL, Roberts PL, Corey L. Association between genital ulcer disease and acquisition of HIV infection in homosexual men. JAMA 1988;260:1429-33.
7. Johnson RE, Nahmias AJ, Magder LS, et al. A seroepidemiologic survey of the prevalence of herpes simplex virus type 2 infection in the United States. N Engl J Med 1989; 321:7-12.
8. Blower SM, Volberding V. What can modeling tell us about the threat of antiviral drug resistance? Curr Opin Infect Dis 2002; 15:609-14.
9. Blower SM, Schwartz EJ, Mills J. Forecasting the future of HIV epidemics: the impact of antiretroviral therapies and imperfect vaccines. AIDS Rev 2003; 5:113-25.
10. Velasco-Hernandez JX, Gershengorn HB, Blower SM. Could widespread use of combination antiretroviral therapy eradicate HIV epidemics? Lancet Infect Dis 2002; 2:487-93.
11. Blower SM, Farmer P. Predicting the public health impact of antiretrovirals: preventing HIV in developing countries. AIDScience 2003; 3.
12. Blower SM, Small PM, Hopewell PC. Control strategies for tuberculosis epidemics: new models for old problems. Science 1996; 273:497-500.
13. Anderson RM, May RM. Coevolution of hosts and parasites. Parasitology 1982; 85:411-26.
14. Bremermann HJ, Thieme HR. A competitive exclusion principle for pathogen virulence. J Math Biol 1989; 27:179-90.
15. Lietman T, Porco T, Blower S. Leprosy and tuberculosis: the epidemiological consequences of cross-immunity. Am J Public Health 1997; 87:1923-7.
16. Dietz K. Epidemiologic interference of two virus populations. J Math Biol 1979; 8:291-300.
17. Robinson NJ, Mulder DW, Auvert B, Hayes RJ. Proportion of HIV infections attributable to other sexually transmitted diseases in a rural Ugandan population: simulation model estimates. Int J Epidemiol 1997; 26:180-9.
18. Wasserheit JN. Epidemiologic synergy: interrelationships between human immunodeficiency virus infection and other sexually transmitted diseases. Sex Transm Dis 1992; 19:61-77.
19. Greenblatt RM, Lukehart SA, Plummer FA, et al. Genital ulceration as a risk factor for human immunodeficiency virus infection. AIDS 1988; 2:47-50.
20. Holmberg SD, Stewart JA, Gerber R, et al. Prior herpes simplex virus type 2 infection as a risk factor for HIV infection. JAMA 1988; 259:1048-50.
21. Bogaerts J, Ricart CA, Van Dyck E, Piot P. The etiology of genital ulceration in Rwanda. Sex Transm Dis 1989; 16:123-6.
22. Beyrer C, Jitwatcharanan K, Natpratan C, et al. Molecular methods for the diagnosis of genital ulcer disease in a sexually transmitted disease clinic population in northern Thailand: predominance of herpes simplex virus infection. J Infect Dis 1998; 178:243-6.
23. Morse SA, Trees DL, Htun Y, et al. Comparison of clinical diagnosis and standard laboratory and molecular methods for the diagnosis of genital ulcer disease in Lesotho: association with human immunodeficiency virus infection. J Infect Dis 1997; 175:583-9.
24. Krone MR, Wald A, Tabet SR, Paradise M, Corey L, Celum CL. Herpes simplex virus type 2 shedding in human immunodeficiency virus-negative men who have sex with men: frequency, patterns, and risk factors. Clin Infect Dis 2000; 30:261-7.
25. Renzi C, Douglas JM, Foster M, et al. Herpes simplex virus type 2 infection as a risk factor for human immunodeficiency virus acquisition in men who have sex with men. J Infect Dis 2003; 187:19-25.
26. Wald A, Link K. Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. J Infect Dis 2002; 185:45-52.
27. Cunningham AL, Turner RR, Miller AC, Para MF, Merigan TC. Evolution of recurrent herpes simplex lesions: an immunohistologic study. J Clin Invest 1985; 75:226-33.
28. Koelle DM, Abbo H, Peck A, Ziegweld K, Corey L. Direct recovery of herpes simplex virus (HSV)-specific T lymphocyte clones from recurrent genital HSV-2 lesions. J Infect Dis 1994; 169:956-61.
29. Kreiss JK, Coombs R, Plummer F, et al. Isolation of human immunodeficiency virus from genital ulcers in Nairobi prostitutes. J Infect Dis 1989; 160:380-4.
30. Schacker T, Ryncarz AJ, Goddard J, Diem K, Shaughnessy M, Corey L. Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men. JAMA 1998;280:61-6.
31. Mbopi-Keou FX, Gresenguet G, Mayaud P, et al. Interactions between herpes simplex virus type 2 and human immunodeficiency virus type 1 infection in African women: opportunities for intervention. J Infect Dis 2000; 182:1090-6.
32. Schacker T, Zeh J, Hu H, Shaughnessy M, Corey L. Changes in plasma human immunodeficiency virus type 1 RNA associated with herpes simplex virus reactivation and suppression. J Infect Dis 2002; 186:1718-25.
33. Schacker T, Zeh J, Hu HL, Hill J, Corey L. Frequency of symptomatic and asymptomatic herpes simplex virus type 2 reactivations among human immunodeficiency virus-infected men. J Infect Dis 1998; 178:1616-22.
34. Latif AS, Katzenstein DA, Bassett MT, Houston S, Emmanuel JC, Marowa E. Genital ulcers and transmission of HIV among couples in Zimbabwe. AIDS 1989; 3:519-23.
35. Cameron DW, Simonsen JN, D'Costa LJ, et al. Female to male transmission of human immunodeficiency virus type 1: risk factors for seroconversion in men. Lancet 1989; 2:403-7.
36. Gray RH, Wawer MJ, Brookmeyer R, et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 2001; 357:1149-53.
37. Blower SM, Porco TC, Darby G. Predicting and preventing the emergence of antiviral drug resistance in HSV-2. Nat Med 1998; 4:673-8.
38. Gershengorn HB, Blower SM. The impact of antivirals and the emergence of drug resistance: HSV-2 epidemic control. AIDS Patient Care STDs 2000; 14:133-42.
39. Gershengorn HB, Darby G, Blower SM. Predicting the emergence of drug-resistant HSV-2: new predictions. BMC Infect Dis 2003; 3:1.
40. Blower SM, Gershengorn HB, Grant RM. A tale of two futures: HIV and antiretroviral therapy in San Francisco. Science 2000; 287:650-4.
41. Blower SM, Aschenbach AN, Gershengorn HB, Kahn JO. Predicting the unpredictable: transmission of drug-resistant HIV. Nat Med 2001; 7:1016-20.
42. Blower SM, Dowlatabadi H. Sensitivity and uncertainty analysis of complex models of disease transmission: an HIV model, as an example. Int Stat Rev 1994; 62:229-43.
43. Catania JA, Coates TJ, Stall R, et al. Prevalence of AIDS-related risk factors and condom use in the United States. Science 1992; 258:1101-6.
44. Katz MH, Schwarcz SK, Kellog TA, et al. Impact of highly active antiretroviral treatment on HIV seroincidence among men who have sex with men: San Francisco. Am J Public Health 2002; 92:388-94.
45. Ashley RL, Wu L, Pickering JW, Tu MC, Schnorenberg L. Premarket evaluation of a commercial glycoprotein-G based enzyme immunoassay for herpes simplex virus type-specific antibodies. J Clin Microbiol 1998; 36:294-5.
46. Ashley RL, Wald A, Eagleton M. Premarket evaluation of the POCkit HSV-2 type-specific serologic test in culture-documented cases of genital herpes simplex virus type 2. Sex Transm Dis 2000; 27:266-9.
47. Wald A, Zeh J, Barnum G, Davis LG, Corey L. Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir. Ann Intern Med 1996; 124:8-15.
48. Corey L, Wald A, Patel R, et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med 2004; 350:11-20.
49. Schacker T, Zeh J, Hu H, et al. Changes in plasma human immunodeficiency virus type 1 RNA associated with herpes simplex virus reactivation and suppression. J Infect Dis 2002; 186:1718-25.